Source: Virtual Congress 2020 – Tuberculosis: part 2
Disease area: Paediatric lung diseases, Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
A. Strzelak (Warszawa, Poland), A. Komorowska-Piotrowska (Warszawa, Poland), A. Borowa (Otwock, Poland), M. Krasinska (Otwock, Poland), W. Feleszko (Warszawa, Poland), M. Kulus (Warszawa, Poland). IP-10 decreases during antituberculous treatment in children with active tuberculosis.. 5302

Member's Comments

No comment yet.

Related content which might interest you: Isoniazid hepatotoxicity associated with treatment of latent tuberculosis in patients on anti-TNF treatment Source: Annual Congress 2007 - Clinical tuberculosis Year: 2007 One year follow-up of T-SPOT. TB results in treated patients with active tuberculosis Source: Annual Congress 2007 - New perspectives and old problems in diagnosing tuberculosis infection and disease Year: 2007 Modulations of the M. tuberculosis-specific IFN-gamma levels during anti-tuberculosis treatment in children Source: Annual Congress 2009 - Tuberculosis at different age groups Year: 2009 Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018 Side effects of antituberculosis drugs in treatment of patients with newly detected pulmonary tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 197s Year: 2007 Our approach about latent tuberculosis infection in patients who are given anti-TNF alpha therapy Source: Annual Congress 2009 - Clinical immunology of tuberculosis Year: 2009 The debacillisation rate during controlled anti-TB therapy Source: Annual Congress 2005 - Information for the active clinician Year: 2005 Diaskintest at patients after successful treatment of lung tuberculosis Source: International Congress 2017 – Migrants and screening Year: 2017 The causes of ineffectiveness of treatment of tuberculosis in children Source: Eur Respir J 2005; 26: Suppl. 49, 649s Year: 2005 Treatment of latent tuberculosis infection with 6 months isoniazid therapy in pediatric population Source: Eur Respir J 2005; 26: Suppl. 49, 624s Year: 2005 Comparison of two different cohorts of patients for multidrug-resistant tuberculosis treatment evaluation Source: Annual Congress 2006 - Epidemiology and management of multidrug-resistant tuberculosis (MDR-TB) Year: 2006 Comparison of compliance of two therapeutic regimens in treatment of latent tuberculosis infection in Belgrade children Source: Eur Respir J 2004; 24: Suppl. 48, 648s Year: 2004 The efficacy of treatment of patients with drug resistant tuberculosis Source: Eur Respir J 2007; 30: Suppl. 51, 661s Year: 2007 Do empiric antibiotics delay appropriate antituberculosis medication in patients with active pulmonary tuberculosis? Source: Annual Congress 2008 - Problems in managing pulmonary and extrapulmonary tuberculosis Year: 2008 Timing of concurrent highly active antiretroviral therapy (HAART) in adults with tuberculosis Source: Eur Respir J 2006; 28: Suppl. 50, 302s Year: 2006 The efficiency of including the II-line drugs to the treatment regimen of isoniazid-resistant tuberculosis. Source: International Congress 2017 – MDRTB: detection and management Year: 2017 Antituberculosis activity of rifabutin in vitro and in patients with pulmonary drug resistant tuberculosis Source: Eur Respir J 2003; 22: Suppl. 45, 524s Year: 2003 Antituberculous activity of fiurenizid in vitro and in patients with destructive pulmonary tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 724s Year: 2004 Patient choice promotes adherence in preventive treatment for latent tuberculosis Source: Eur Respir J 2007; 30: 728-735 Year: 2007 Long-term results of treatment with bedaquiline in patients with drug-resistant tuberculosis Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020